{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T08:36:37Z","timestamp":1770798997555,"version":"3.50.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.biopha.2013.04.006","type":"journal-article","created":{"date-parts":[[2013,5,7]],"date-time":"2013-05-07T19:46:48Z","timestamp":1367956008000},"page":"527-532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells"],"prefix":"10.1016","volume":"67","author":[{"given":"Hatice Demet","family":"Kiper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burcin","family":"Tezcanli Kaymaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysun Adan","family":"Gokbulut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur","family":"Selvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cigir Biray","family":"Avci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Buket","family":"Kosova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guniz","family":"Iskender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melis Kartal","family":"Yandim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cumhur","family":"Gunduz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahri","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf","family":"Baran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guray","family":"Saydam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2013.04.006_bib0005","first-page":"161","article-title":"Imatinib mesylate and the management of chronic myeloid leukemia (CML)","volume":"22","author":"Koca","year":"2005","journal-title":"Turk J Hematol"},{"key":"10.1016\/j.biopha.2013.04.006_bib0010","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2013.04.006_bib0015","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/shem.2003.50044","article-title":"Molecular monitoring of chronic myeloid leukemia","volume":"40","author":"Hughes","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.biopha.2013.04.006_bib0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor Imatinib in chronic phase and blast crisis chronic myelogenous leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2013.04.006_bib0025","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1056\/NEJMe068073","article-title":"Circumventing resistance to kinase-inhibitor therapy","volume":"354","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2013.04.006_bib0030","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2013.04.006_bib0035","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2013.04.006_bib0040","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2002-04-1204","article-title":"Signal transducer and activator of transcription proteins in leukemias","volume":"101","author":"Benekli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2013.04.006_bib0045","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF02258360","article-title":"Activation of STAT transcription factors in oncogenic tyrosine kinase signaling","volume":"5","author":"Garcia","year":"1998","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.biopha.2013.04.006_bib0050","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.onc.1203527","article-title":"STATs in oncogenesis","volume":"19","author":"Bowman","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2013.04.006_bib0055","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.biopha.2013.04.006_bib0060","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.1073\/pnas.93.15.7673","article-title":"Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma","volume":"93","author":"Bromberg","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopha.2013.04.006_bib0065","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/sj.onc.1203480","article-title":"Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice","volume":"19","author":"Levy","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2013.04.006_bib0070","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1074-7613(00)80011-4","article-title":"Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells","volume":"10","author":"Catlett-Falcone","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.biopha.2013.04.006_bib0075","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1046\/j.1365-2141.2001.02575.x","article-title":"Interferon alpha extends the survival of human myeloma cells through an upregulation of the Mcl-1 antiapoptotic molecule","volume":"112","author":"Puthier","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.biopha.2013.04.006_bib0080","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","article-title":"The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel","volume":"84","author":"Jagdev","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.biopha.2013.04.006_bib0085","first-page":"2602","article-title":"Bisphosphonate treatment inhibits the growth of prostate cancer cells","volume":"61","author":"Lee","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2013.04.006_bib0090","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0305-7372(02)00095-6","article-title":"The anti-tumour activity of bisphosphonates","volume":"28","author":"Neville-Webbe","year":"2002","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.biopha.2013.04.006_bib0095","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/sj.bjc.6600986","article-title":"Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro","volume":"88","author":"Tassone","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.biopha.2013.04.006_bib0100","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-10-3862","article-title":"High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo","volume":"71","author":"Benzaid","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2013.04.006_bib0105","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/annonc\/mdr159","article-title":"Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer","volume":"23","author":"Gallo","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.biopha.2013.04.006_bib0110","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bone.2010.09.035","article-title":"Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase","volume":"48","author":"Stresing","year":"2011","journal-title":"Bone"},{"issue":"Suppl. 2","key":"10.1016\/j.biopha.2013.04.006_bib0115","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1542\/peds.2006-2023H","article-title":"Bisphosphonates: mode of action and pharmacology","volume":"119","author":"Russell","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.biopha.2013.04.006_bib0120","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood-2003-01-0305","article-title":"The third-generation bisphosphonate Zoledronic Acid synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate","volume":"102","author":"Kuroda","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2013.04.006_bib0125","first-page":"23","article-title":"Synergistic effect of imatinib mesylate and fludarabine combination on Philadelphia chromosome-positive chronic myeloid leukemia cell lines","volume":"24","author":"Piskin","year":"2007","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.biopha.2013.04.006_bib0130","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10428199809059253","article-title":"Anti-tumour activity of bisphosphonates in human myeloma cells","volume":"32","author":"Shipman","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.biopha.2013.04.006_bib0135","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1054\/bjoc.1999.1131","article-title":"Bisphosphonates induce apoptosis in human breast cancer cell lines","volume":"82","author":"Senaratne","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.biopha.2013.04.006_bib0140","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/sj.bjc.6600476","article-title":"The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro","volume":"87","author":"Riebeling","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.biopha.2013.04.006_bib0145","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00001813-200106000-00007","article-title":"The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro","volume":"12","author":"Sonnemann","year":"2001","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.biopha.2013.04.006_bib0150","first-page":"453","article-title":"Exploring the anti-tumour activity of bisphosphonates in early breast cancer","volume":"34","author":"Winter","year":"2008","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.biopha.2013.04.006_bib0155","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF02983531","article-title":"Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines","volume":"79","author":"Kimura","year":"2004","journal-title":"Int J Hematol"},{"key":"10.1016\/j.biopha.2013.04.006_bib0160","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2141.2005.05648.x","article-title":"Zoledronic Acid synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth","volume":"130","author":"Segawa","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.biopha.2013.04.006_bib0165","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/sj.leu.2403949","article-title":"Zoledronic Acid inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells","volume":"19","author":"Chuah","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2013.04.006_bib0170","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2141.2007.06578.x","article-title":"Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I\/II study in patients in complete haematological remission","volume":"137","author":"Pavlu","year":"2007","journal-title":"Br J Haematol"},{"issue":"2 Suppl. 6","key":"10.1016\/j.biopha.2013.04.006_bib0175","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0093-7754(01)90262-3","article-title":"Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials","volume":"28","author":"Berenson","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.biopha.2013.04.006_bib0180","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/009127002762491316","article-title":"Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases","volume":"42","author":"Chen","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.biopha.2013.04.006_bib0185","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","article-title":"A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V","volume":"184","author":"Vermes","year":"1995","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.biopha.2013.04.006_bib0190","first-page":"1724","article-title":"BCR\/ABL leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats","volume":"10","author":"Frank","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2013.04.006_bib0195","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1182\/blood.V99.1.252","article-title":"Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival","volume":"99","author":"Benekli","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2013.04.006_bib0200","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1182\/blood.V97.9.2846","article-title":"Down-regulation of interleukin-3\/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition","volume":"97","author":"Donato","year":"2001","journal-title":"Blood"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332213000607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332213000607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:51:53Z","timestamp":1760093513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332213000607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0753332213000607"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2013.04.006","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2013.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}